Supply of CAR-T therapy Lisocabtagene maraleucel for Polish healthcare.
Some language patterns suggest this RFP may be written for a specific incumbent vendor. Review qualification requirements and brand-specific terms carefully before committing bid resources.
The contracting authority is procuring the supply of the medicinal product Lisocabtagene maraleucel (a CAR-T cell therapy) for the treatment of patients. The buyer is a Polish healthcare entity, likely a hospital or regional health authority. The notice specifies the exact brand/product, indicating a tailored requirement. The contract duration and value are not specified, but the product is a specialized, high-cost therapy.